Kine Sciences Announces First Patient Dosed in the Phase 1b/ 2a Study in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Kine Sciences United Kingdom United States of America South Korea

The first patient was dosed in the Phase 1b/2a dose escalation trial of KINE-101.This study is conducted in Korea in patients with CIDP who have received at least one frontline treatment regimen. Kine Sciences advanced KINE-101 to the Phase 1b/2a study following the successful completion of a Phase 1 study in the US.KINE-101 is a disease modifier nanopeptide that acts by activating Treg cells.View original content:https://www.prnewswire.co.uk/news-releases/kine-sciences-announces-first-patient-dosed-in-the-phase-1b2a-study-in-patients-with-chronic-inflammatory-demyelinating-polyneuropathy-cidp-302246639.html